|Bid||320.85 x 0|
|Ask||0.00 x 0|
|Day's Range||311.85 - 311.85|
|52 Week Range||252.70 - 311.85|
|PE Ratio (TTM)||55.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Procter & Gamble is turning the tables on Nelson Peltz, the activist investor who wants the consumer goods group to address what he calls "chronic underperformance". As it fights to stop Mr Peltz ...
The consumer product giant unveiled the homework it has done on Peltz, who is engaged in proxy fight for a board seat.
Procter & Gamble released a hefty report taking aim at Trian Fund Management's uneven history of delivering results, escalating the proxy fight between the consumer product giant and Nelson Peltz's firm. Trian disclosed its stake in P&G (PG) February in a filing with the Securities & Exchange Commission and Peltz requested a seat on the company's board privately (P&G declined), and then, publicly in July. Peltz laid out his case in a 94-page presentation early September.